NovaBridge Biosciences (ADR) (NBP)
Develops asset-focused oncology and retinal-disease programs through dedicated therapeutic subsidiaries.
Something off on this page? Send us feedback.
Develops givastomig for oncology and VIS-101 for retinal disease through an asset-focused biotechnology platform. The post-divestiture company works through dedicated therapeutic subsidiaries, including Visara for VIS-101.
Develops givastomig, its lead oncology program, and VIS-101, a biologic for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. These programs form the core of an asset-focused biotechnology platform.
VIS-101 sits in Visara, a therapeutic-asset subsidiary that holds rights outside Greater China and specified other Asian countries. Separately, the company acquired Bridge Health, whose Claudin 18.2 parental antibody supports bispecific and multispecific applications related to givastomig.
After divesting its Greater China operating business and portfolio rights, the company operates with a small team and external collaborations. The post-divestiture structure uses dedicated therapeutic-asset subsidiaries for operational focus, oversight, and risk management.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $30.1M · Total debt $438.5K · Total assets $37.2M · Shareholders' equity $33.0M
- Revenue
- $0
- Operating income
- −$10.4M
- Net income
- −$4.4M
Reported in CNY, converted at the latest exchange rate
No dividends on record.
50.12M ADS as of Aug 21, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Sean Wuxiong Cao1Insiderdirector, officer: See Remarks | — | — | Form 4filed May 18, 2026 ↗ |
Phillip Andrew Dennis1Insiderofficer: Chief Medical Officer | — | — | Form 4filed Jun 22, 2026 ↗ |
Everest Medicines LimitedStrategic | —16.10% of class, as filed | — | 13Dfiled Aug 5, 2025 ↗ |
Wei Fu1Insiderdirector | —11.50% of class, as filed | — | 13Dfiled Feb 3, 2026 ↗ |
Xi-Yong Fu1Insiderdirector, officer: See Remarks | — | — | Form 4filed Mar 18, 2026 ↗ |
| See all 15 → | |||
- This position is filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 31, 2026 | Cong Claire Xu | officer: EVP, Clinical Development | −3,282 | $0.7900 |
| Jul 6, 2026 | Cong Claire Xu | officer: SVP, Clinical Development | −4,485 | $0.8900 |
| Jun 18, 2026 | Phillip Andrew Dennis | officer: Chief Medical Officer | −8,494 | $0.6600 |
| Jun 1, 2026 | Cong Claire Xu | officer: SVP, Clinical Development | −3,494 | $3.94 |
| May 14, 2026 | Sean Wuxiong Cao | director, officer: See Remarks | −21,399 | $1.99 |
- Regeneron
Anti-VEGF retinal therapy across wet AMD, DME and RVO
- AstraZeneca (ADR)
CLDN18.2 oncology pipeline across ADC and T-cell engager modalities
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NovaBridge Biosciences (ADR) | $1.79 | +0.56% | $206.3M | — | — | — | — |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| AstraZeneca (ADR) | $163.48 | +1.13% | $250.67B | 24.3 | 15.2 | 4.1 | +6.4% |
| Median | 22.7 | 14.6 | 4.9 | +11.6% |